Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lisa Zimmer

Showing results (81-90 of 218) with videos related to

Pageof 22
Sort By:
Cancer Treatment Reviews|February 29, 2016
Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapyThomas K Eigentler, Jessica C Hassel, Carola Berking, et al.
International Journal of Cancer|January 20, 2017
IRF4 rs12203592 functional variant and melanoma survivalMiriam Potrony, Aida Rebollo-Morell, Pol Giménez-Xavier, et al.
BMC Cancer|October 25, 2019
Simultaneous primary cancer occurrence of melanoma and pulmonary adenocarcinoma in leptomeningeal metastases: a case reportAnn-Kathrin Stoppek, Sied Kebir, Andreas Junker, et al.
Cancer Treatment Reviews|May 28, 2017
Combined immune checkpoint blockade (anti-PD-1/anti-CTLA-4): Evaluation and management of adverse drug reactionsJessica C Hassel, Lucie Heinzerling, Jens Aberle, et al.
Nature Immunology|October 21, 2011
Failure to detect production of IL-10 by activated human neutrophilsMartin S Davey, Nicola Tamassia, Marzia Rossato, et al.
Pigment Cell & Melanoma Research|August 1, 2022
Clinical and pathological characteristics of familial melanoma with germline TERT promoter variantsAnne Zaremba, Friedegund Meier, Christian Schlein, et al.
Oncotarget|April 6, 2017
Targeted next generation sequencing of mucosal melanomas identifies frequent NF1 and RAS mutationsIoana Cosgarea, Selma Ugurel, Antje Sucker, et al.
Melanoma Research|October 31, 2018
Clinical experience with combination BRAF/MEK inhibitors for melanoma with brain metastases: a real-life multicenter studyJoshua Z Drago, Donald Lawrence, Elisabeth Livingstone, et al.
Cancer Immunology, Immunotherapy : CII|March 1, 2018
Ipilimumab in metastatic melanoma patients with pre-existing autoimmune disordersKatharina C Kähler, Thomas K Eigentler, Anja Gesierich, et al.
European Journal of Cancer (Oxford, England : 1990)|December 21, 2020
SARS-CoV-2 infections in melanoma patients treated with PD-1 inhibitors: A survey of the German ADOREG melanoma registryRose K C Moritz, Ralf Gutzmer, Lisa Zimmer, et al.
Pageof 22

Showing results (81-90 of 218) with videos related to

Sort By:
Pageof 22
Cancer Treatment Reviews|February 29, 2016
Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapyThomas K Eigentler, Jessica C Hassel, Carola Berking, et al.
International Journal of Cancer|January 20, 2017
IRF4 rs12203592 functional variant and melanoma survivalMiriam Potrony, Aida Rebollo-Morell, Pol Giménez-Xavier, et al.
BMC Cancer|October 25, 2019
Simultaneous primary cancer occurrence of melanoma and pulmonary adenocarcinoma in leptomeningeal metastases: a case reportAnn-Kathrin Stoppek, Sied Kebir, Andreas Junker, et al.
Cancer Treatment Reviews|May 28, 2017
Combined immune checkpoint blockade (anti-PD-1/anti-CTLA-4): Evaluation and management of adverse drug reactionsJessica C Hassel, Lucie Heinzerling, Jens Aberle, et al.
Nature Immunology|October 21, 2011
Failure to detect production of IL-10 by activated human neutrophilsMartin S Davey, Nicola Tamassia, Marzia Rossato, et al.
Pigment Cell & Melanoma Research|August 1, 2022
Clinical and pathological characteristics of familial melanoma with germline TERT promoter variantsAnne Zaremba, Friedegund Meier, Christian Schlein, et al.
Oncotarget|April 6, 2017
Targeted next generation sequencing of mucosal melanomas identifies frequent NF1 and RAS mutationsIoana Cosgarea, Selma Ugurel, Antje Sucker, et al.
Melanoma Research|October 31, 2018
Clinical experience with combination BRAF/MEK inhibitors for melanoma with brain metastases: a real-life multicenter studyJoshua Z Drago, Donald Lawrence, Elisabeth Livingstone, et al.
Cancer Immunology, Immunotherapy : CII|March 1, 2018
Ipilimumab in metastatic melanoma patients with pre-existing autoimmune disordersKatharina C Kähler, Thomas K Eigentler, Anja Gesierich, et al.
European Journal of Cancer (Oxford, England : 1990)|December 21, 2020
SARS-CoV-2 infections in melanoma patients treated with PD-1 inhibitors: A survey of the German ADOREG melanoma registryRose K C Moritz, Ralf Gutzmer, Lisa Zimmer, et al.
Pageof 22